MYMD Stock Overview
A clinical development stage pharmaceutical company, focuses on developing various therapeutic platforms to treat the aging and age-related and autoimmune diseases, and chronic pain, anxiety, and sleep disorders.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
MyMD Pharmaceuticals, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.86 |
| 52 Week High | US$63.90 |
| 52 Week Low | US$1.80 |
| Beta | 2.91 |
| 1 Month Change | -44.14% |
| 3 Month Change | -41.88% |
| 1 Year Change | -96.27% |
| 3 Year Change | -98.62% |
| 5 Year Change | n/a |
| Change since IPO | -98.75% |
Recent News & Updates
Recent updates
We Think MyMD Pharmaceuticals (NASDAQ:MYMD) Needs To Drive Business Growth Carefully
Sep 01
We're Keeping An Eye On MyMD Pharmaceuticals' (NASDAQ:MYMD) Cash Burn Rate
May 19MyMD Pharma receives grant from European patent office for Supera-CBD compound
Aug 30Oramed, MyMD surge on plans for early-stage oral COVID vaccine data release in Q3
Jul 08Companies Like MyMD Pharmaceuticals (NASDAQ:MYMD) Could Be Quite Risky
Apr 12MyMD Pharmaceuticals (NASDAQ:MYMD) Is In A Good Position To Deliver On Growth Plans
Aug 29Shareholder Returns
| MYMD | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | -7.0% | 0.02% | -0.6% |
| 1Y | -96.3% | 15.2% | 22.5% |
Return vs Industry: MYMD underperformed the US Pharmaceuticals industry which returned 15.2% over the past year.
Return vs Market: MYMD underperformed the US Market which returned 22.5% over the past year.
Price Volatility
| MYMD volatility | |
|---|---|
| MYMD Average Weekly Movement | 13.7% |
| Pharmaceuticals Industry Average Movement | 9.8% |
| Market Average Movement | 5.8% |
| 10% most volatile stocks in US Market | 15.7% |
| 10% least volatile stocks in US Market | 2.9% |
Stable Share Price: MYMD's share price has been volatile over the past 3 months.
Volatility Over Time: MYMD's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2014 | 6 | n/a | www.mymd.com |
MyMD Pharmaceuticals, Inc., a clinical development stage pharmaceutical company, focuses on developing various therapeutic platforms to treat the aging and age-related and autoimmune diseases, and chronic pain, anxiety, and sleep disorders. The company is developing MYMD-1, a drug platform based on a clinical stage small molecule that regulates the immunometabolic system and its pro-inflammatory cytokines to treat autoimmune diseases and age-related illnesses, and a Phase 2 clinical trial for multiple sclerosis, diabetes, inflammatory bowel diseases, and rheumatoid arthritis. It is also developing Supera-CBD, a synthetic analog of cannabidiol for treating epilepsy, pain, and anxiety/depression.
MyMD Pharmaceuticals, Inc. Fundamentals Summary
| MYMD fundamental statistics | |
|---|---|
| Market cap | US$4.29m |
| Earnings (TTM) | -US$17.55m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.2x
P/E RatioIs MYMD overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MYMD income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$17.55m |
| Earnings | -US$17.55m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -7.61 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did MYMD perform over the long term?
See historical performance and comparison